Cargando…
Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells
Metastatic dissemination is still one of the major causes of death of melanoma’s patients. KiSS1 is a metastasis suppressor originally identified in melanoma cells, known to play an important physiological role in mammals’ development and puberty. It has been previously shown that expression of KiSS...
Autores principales: | Guzzetti, Carlotta, Corno, Cristina, Vergani, Elisabetta, Mirra, Luca, Ciusani, Emilio, Rodolfo, Monica, Perego, Paola, Beretta, Giovanni L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544897/ https://www.ncbi.nlm.nih.gov/pubmed/37790750 http://dx.doi.org/10.3389/fonc.2023.1182853 |
Ejemplares similares
-
Deregulated FASN Expression in BRAF Inhibitor-Resistant Melanoma Cells Unveils New Targets for Drug Combinations
por: Stamatakos, Serena, et al.
Publicado: (2021) -
Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma
por: Vergani, Elisabetta, et al.
Publicado: (2022) -
Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016) -
Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling
por: Tan, Yufan, et al.
Publicado: (2021) -
Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo
por: Bonner, Michael Y., et al.
Publicado: (2016)